Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2232494 | 1.00 | CA2 (0.40) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL9244068 | 1.00 | CA2 (0.40) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL7298938 | 0.86 | CA2 (0.41) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL7308600 | 0.86 | CA2 (0.41) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| Glycidol SCHEMBL3642624 | 0.81 | MEN1 (0.50) | CA2ALDH1A1CYP2D6MEN1KMT2A | |
| Glycidol SCHEMBL27466561 | 0.81 | MEN1 (0.50) | CA2ALDH1A1CYP2D6MEN1KMT2A | |
| Glycidol SCHEMBL27466559 | 0.81 | MEN1 (0.50) | CA2ALDH1A1CYP2D6MEN1KMT2A | |
| SCHEMBL2115284 | 0.80 | CRBN (0.45) | CA2ALDH1A1NPSR1MEN1KMT2A | |
| SCHEMBL2115280 | 0.80 | CRBN (0.45) | CA2ALDH1A1NPSR1MEN1KMT2A | |
| SCHEMBL6630551 | 0.79 | CA2 (0.56) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044197-B1 | HALOGENATED COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2018-11-07 | — | — | EP | disclosed |
| US-20160367707-A1 | HALOGENATED COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| US-9375496-B2 | Halogenated compounds for cancer imaging and treatment and methods for their use | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2016-06-28 | — | — | US | disclosed |
| US-9206206-B2 | Oxidized lipid compounds and uses thereof | VASCULAR BIOGENICS LTD. (IL) | 2015-12-08 | — | — | US | disclosed |
| US-20150125389-A1 | HALOGENATED COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-05-07 | — | — | US | disclosed |
| EP-2826369-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2826370-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2348866-B1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD (IL) | 2015-01-07 | — | — | EP | disclosed |
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | VASCULAR BIOGENICS LTD. (IL) | 2013-08-08 | — | — | US | disclosed |
| CN-102271517-A | oxidized lipid compounds and uses thereof | — | 2011-12-07 | — | — | CN | disclosed |
| WO-2010052718-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2010-05-14 | — | — | WO | disclosed |
| US-6673931-B2 | (4-(4-(3-(2-METHOXY-BENZYLOXY)-PROPOXY)-PHENYL)-5-(4-METHOXY -NAPHTHALEN-2-YLMETHOXY)-PIPERIDIN-3-YL)-METHANOL FOR EXAMPLE; USE TREATING RESTENOSIS, GLAUCOMA, CARDIAC AND KIDNEY INSUFFICIENCY | HOFFMAN-LA ROCHE INC. | 2004-01-06 | — | — | US | disclosed |
| EP-1074549-B1 | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors | HOFFMANN LA ROCHE (CH) | 2003-11-19 | — | — | EP | disclosed |
| US-20020087002-A1 | Naphthalenyl piperidines as renin inhibitors | NOVARTIS AG (CH) | 2002-07-04 | — | — | US | disclosed |
| US-6376672-B1 | RESTENOSIS; VISION DEFECTS; CARDIOVASCULAR DISORDERS; KIDNEY DIEASES | HOFFMANN-LA ROCHE INC. | 2002-04-23 | — | — | US | disclosed |
| US-6218385-B1 | FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS | HOFFMANN-LA ROCHE INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1074549-A2 | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-07 | — | — | EP | disclosed |
| US-5574055-A | COGNITIVE AND NEURODEGENERATIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0535042-B1 | ANGIOTENSIS CONVERTING ENZYME INHIBITORS | FISONS PLC (GB) | 1995-03-29 | — | — | EP | disclosed |
| US-5348978-A | Angiotensin converting enzyme inhibitors | FISONS PLC (GB) | 1994-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367707-A1 | HALOGENATED COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | KLK3, F12, RXFP3 | CA2 1350/4885TMEM97 3129/4885SIGMAR1 758/4885 |
| US-20020087002-A1 | Naphthalenyl piperidines as renin inhibitors | REN, TNNI3, PTGIS | CA2 1719/4885TMEM97 3552/4885SIGMAR1 4471/4885 |
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | LPO, GPX4, ALOX15B | CA2 3456/4885TMEM97 1801/4885SIGMAR1 1671/4885 |
| US-20150125389-A1 | HALOGENATED COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | KLK3, RXFP3, F12 | CA2 1328/4885TMEM97 3049/4885SIGMAR1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.